{
    "Trade/Device Name(s)": [
        "iDart Lyme IgG ImmunoBlot Kit"
    ],
    "Submitter Information": "ID-FISH Technology, Inc.",
    "510(k) Number": "K233367",
    "Predicate Device Reference 510(k) Number(s)": [
        "K220016"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "July 5, 2024",
    "Summary Letter Received Date": "July 8, 2024",
    "Submission Date": "July 30, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema Pallidum Treponemal Test Reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoblot assay",
        "Line immunoblot"
    ],
    "Methodologies": [
        "Qualitative antibody detection"
    ],
    "Submission Type(s)": [
        "Kit",
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for iDart Lyme IgG ImmunoBlot Kit, a qualitative immunoblot assay for detecting IgG antibodies to Borrelia burgdorferi in human serum to aid in Lyme disease diagnosis.",
    "Indications for Use Summary": "Qualitative detection of IgG antibodies to Borrelia burgdorferi in human serum, to aid in the diagnosis of Lyme disease in patients with clinical history, signs, and symptoms consistent with Lyme disease; not for screening asymptomatic patients.",
    "fda_folder": "Microbiology"
}